Fig. 2.

Schematic representation of possible use of NOX2 inhibitors in schizophrenia. a Available antipsychotic compounds inhibit excessive dopaminergic transmission, but not curative and are associated with considerable side effects. b From experimental data, it emerges that NOX2 activation could be the primary source of neurotransmission alterations, which lead to psychotic symptoms. Therefore, blocking NOX2 activation could represent a novel therapeutic approach